Elan

Perrigo cuts 800 jobs

Friday, October 23, 2015

Perrigo has announced a $2 billion share repurchase plan. The plan includes $500 million in repurchases that will be completed by the end of 2015, and an additional $1.5 billion in repurchases that the company expects to complete over the subsequent 24 to 36 months, which are expected to be funded through available liquidity. Perrigo also will reduce its workforce by about 800 employees, or 6% of its current global headcount.

[Read More]

Perrigo names board of directors

Friday, December 20, 2013

Dublin, Ireland-based Perrigo has announced the appointment of its board of directors, effective until Perrigo’s annual general meeting scheduled for November 2014. The appointment of the Perrigo board follows the completion of Perrigo’s acquisition of Elan in a cash and stock transaction valued at approximately $8.6 billion. The transaction will create a global healthcare company with a growth profile.

[Read More]

Elan shareholders approve one of four transactions

Monday, June 17, 2013

Elan shareholders approved one of four transactions up for a vote at its special meeting Monday. Shareholders rejected plans for a $1 billion cash acquisition of a 21% stake in Theravance’s royalties from the respiratory franchise it shares with GSK; acquisition of Vienna, Austria-based AOP Pharmaceuticals for $348.8 million; and the spinout of ELND005 into a new Irish startup Speranza Therapeutics, with $70 million in funding.

[Read More]